↓ Skip to main content

Bispecific antibodies in cancer immunotherapy

Overview of attention for article published in Therapeutic Advances in Vaccines and Immunotherapy, March 2018

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

twitter
14 X users
patent
87 patents
facebook
1 Facebook page

Readers on

mendeley
306 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Bispecific antibodies in cancer immunotherapy
Published in
Therapeutic Advances in Vaccines and Immunotherapy, March 2018
DOI 10.1177/2515135518763280
Pubmed ID
Authors
Abstract

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeutic bispecific antibodies: (a) cytotoxic effector cell redirectors; (b) tumor-targeted immunomodulators; and (c) dual immunomodulators. Cytotoxic effector cell redirectors are dominated by T-cell redirecting compounds, bispecific compounds engaging a tumor-associated antigen and the T-cell receptor/CD3 complex, thereby redirecting T-cell cytotoxicity to malignant cells. This is the most established class of bispecific immunotherapies, with two compounds having reached the market and numerous compounds in clinical development. Tumor-targeted immunomodulators are bispecific compounds binding to a tumor-associated antigen and an immunomodulating receptor, such as CD40 or 4-1BB. Such compounds are usually designed to be inactive until binding the tumor antigen, thereby localizing immune stimulation to the tumor environment, while minimizing immune activation elsewhere. This is expected to induce powerful activation of tumor-specific T cells with reduced risk of immune-related adverse events. Finally, dual immunomodulators are bispecific compounds that bind two distinct immunomodulating targets, often combining targeting of PD-1 or PD-L1 with that of LAG-3 or TIM-3. The rationale is to induce superior tumor immunity compared to monospecific antibodies to the same targets. In this review, we describe each of these classes of bispecific antibodies, and present examples of compounds in development.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 306 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 306 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 55 18%
Student > Ph. D. Student 38 12%
Student > Bachelor 37 12%
Student > Master 33 11%
Other 22 7%
Other 33 11%
Unknown 88 29%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 75 25%
Agricultural and Biological Sciences 33 11%
Immunology and Microbiology 33 11%
Medicine and Dentistry 25 8%
Pharmacology, Toxicology and Pharmaceutical Science 15 5%
Other 31 10%
Unknown 94 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2026.
All research outputs
#1,507,321
of 33,849,731 outputs
Outputs from Therapeutic Advances in Vaccines and Immunotherapy
#9
of 78 outputs
Outputs of similar age
#25,331
of 370,946 outputs
Outputs of similar age from Therapeutic Advances in Vaccines and Immunotherapy
#1
of 3 outputs
Altmetric has tracked 33,849,731 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 78 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 370,946 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them